目的 探究喘可治注射液联合沙美特罗替卡松治疗支气管哮喘慢性持续期的临床疗效。方法 选取2012年1月-2015年12月在四川省人民医院接受治疗的支气管哮喘持续期患者96例，随机分为对照组和治疗组，每组各48例。对照组患者接受沙美特罗替卡松粉吸入剂治疗，1吸/次，2次/d。治疗组患者在对照组的治疗基础上肌肉注射喘可治注射液，4 mL/次，2次/d。两组均连续治疗40 d。观察两组的临床疗效，同时比较两组患者治疗前后肺功能指标和ACT积分的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为89.58%、100.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的肺活量、用力肺活量、第一秒用力肺活量均较治疗前显著提高，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组肺活量、用力肺活量、第一秒用力肺活量高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组ACT积分高于同组治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组ACT积分高于对照组，两组比较差异有统计学意义（P<0.05）。结论 喘可治注射液联合沙美特罗替卡松具有较好的临床疗效，可明显改善患者的肺功能，缓解支气管哮喘慢性持续期的症状，具有一定的临床推广应用价值。

Objective To explore the effect of Chuankezhi Injection combined with salmeterol in treatment of chronic duration of bronchial asthma. Methods Patients (96 cases) with bronchial asthma in chronic duration in Sichuan Provincial People's Hospital from January 2012 to December 2015 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were received Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation, 1absorption/time, twice daily. Patients in the treatment group were im administered with Chuankezhi Injection on the basis of the control group, 4 mL/time, twice daily. Patients in two groups were treated for 40 d. After treatment, the efficacy was evaluated, and the changes of indicators of pulmonary function and ACT integral in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 89.58% and 100.00%, respectively, and there were differences between two groups (P<0.05). After treatment, vital capacity, forced vital capacity, and forced vital capacity in the first second in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, vital capacity, forced vital capacity, and forced vital capacity in the first seconds in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, ACT integrals in two group were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, ACT integral in the treatment group was higher than that in the control group, with significant difference between two groups (P<0.05). Conclusion Chuankezhi Injection combined with salmeterol has clinical curative effect in treatment of chronic duration of bronchial asthma, and can obviously improve the lung function, and alleviate the symptoms of bronchial asthma chronic duration, which has a certain clinical application value.